Teva (TEVA) said late Thursday it submitted a new drug application to the US Food and Drug Administration for ecopipam investigational therapy to treat pediatric Tourette syndrome, a chronic neuro-developmental disorder.
The NDA submission is supported by phase 3 data, which showed ecopipam sharply delayed time to relapse compared with placebo in pediatric Tourette patients who had attained a clinical response during the open-label treatment period, the company said.
Ecopipam has secured Orphan Drug and Fast Track designations from the FDA for the treatment of Tourette syndrome in pediatric patients, according to a statement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments